# US 2005/0090504 A1 · Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0090504 A1
- Document ID: US20050090504A1
- Status: Published application
- Kind: A1
- Application number: 10/972,564
- Filed: 2004-10-25
- Published: 2005-04-28
- Earliest claimed: 2003-10-24
- Inventors: Leyi Gong; Robert Wilhelm
- Web page: https://patentgrep.com/patent/US20050090504A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 233/36: with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 239/80: Oxygen atoms
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 277/82: Nitrogen atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds having the Formula (I), are useful as CCR3 receptor antagonists, wherein Ar is aryl or heteroaryl; Q is —C(═O)— or C1-2alkylene; X is N(+)R9a, or N; Y is CR9b, or N; R2 is hydrogen or alkyl; R3 and R4 are as defined in the specification; Uc is a mono- or bicyclic group as defined in the specification; n is 0 or 1; and p is 0, 1, 2, 3 or 4.

## Claims

### Claim 1

A compound having the Formula (I):
wherein:
Ar is aryl or heteroaryl;
Q is —C(═O)— or C1-2alkylene;
X is N, or N+R9a Z−; Y is CR9a or N;
Z is a pharmaceutically acceptable anion;
R2 is hydrogen or alkyl;
R3 and R4 are, independently of each other, hydrogen, C1-8 alkyl, substituted alkyl, C2-8 alkenyl, C3-7 cycloalkyl, aryl, heteroaryl, heterocyclyl, heteroalkyl, —(C1-8 alkylene)-C(═O)-Z1, or —(C1-8alkylene)-C(O)2Z1, wherein Z1 is C1-8 alkyl, C1-8 haloalkyl, C1-8 alkoxy, C1-8 haloalkoxy, hydroxy, amino, alkylamino, aryl, aryl C1-8 alkyl, aryloxy, aryl C1-8 alkyloxy, heteroaryl, or heteroaryloxy;
Uc is selected from one of (S), (T), (V), and (W),
wherein T1 is O, S, or NR5, wherein R5 is selected from hydrogen, C1-8 alkyl, substituted C1-8 alkyl, C3-7 cycloalkyl, and heterocyclyl; and V1 and W1 define an optionally substituted five-to-six membered heterocyclic ring; provided that when Uc is T and T1 is S, then at least one of R3 and R4 is not hydrogen, and further provided that when both X and Y are N, Uc is not T;
R9 is attached to any available carbon atom of the piperidinyl or piperazinyl ring and is selected from the group consisting of hydroxy, lower alkoxy, oxo (═O), halogen, cyano, halo C1-4 alkyl, halo C1-4 alkoxy, and C1-4 lower alkyl optionally substituted with one to two R15;
R9a and R9b are selected from the group consisting of hydrogen and C1-8 alkyl optionally substituted with one to two R15;
R10 is attached to any available carbon atom of the benzo or phenyl ring and at each occurrence is independently selected from the group consisting of C1-8 alkyl, substituted C1-8 alkyl, hydroxy, C1-8 alkoxy, halogen, cyano, C1-8 haloalkoxy, amino, alkylamino, heterocyclyl, heteroaryl, C3-7 cycloalkyl, or phenyl said heterocyclyl, heteroaryl, C3-7 cycloalkyl and phenyl bring optionally substituted by one to three substituents independently selected from R16;
R15 at each occurrence is independently selected from the group consisting of hydroxy, C1-4 alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, amino, and alkylamino;
R16 at each occurrence is independently selected from the group consisting of C1-4 alkyl, hydroxy, C1-4 alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, amino, and alkylamino;
m is 0, 1, 2, 3, or 4;
n is 0 or 1;
p is 0, 1, 2, 3 or 4; and,
pharmaceutically-acceptable salts thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein Uc is T, and R4 is methyl, ethyl, 1-methylethyl, isopropyl, 1-hydroxyethyl or 2-hydroxyethyl.

### Claim 3 (depends on 1)

A compound according to claim 1 wherein:
Ar is pyrimidinyl or optionally-substituted phenyl;
Q is CH2;
R2 is hydrogen;
R3 and R4 are, independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl;
R9 is selected from the group consisting of methyl, ethyl, hydroxy, methoxy, oxo (═O), halo, and cyano;
R9a and R9b are independently selected from the group consisting of hydrogen, methyl and ethyl;
n is 1; and
p is 0 or 1.

### Claim 4 (depends on 1)

A compound according to claim 1 wherein X is N and Y is CR9b.

### Claim 5 (depends on 1)

A compound according to claim 1 wherein X and Y are both N.

### Claim 6 (depends on 1)

A compound according to claim 1 wherein X is N+R9a Z−, and Y is CR9b.

### Claim 7 (depends on 1)

A compound according to claim 1 wherein
Uc is IIIa.
R10 is selected from C1-4 alkyl, halogen, cyano, and C1-4 alkoxy; and
m is 0, 1, or 2.

### Claim 8 (depends on 1)

A compound according to claim 1 wherein:
Uc optionally substituted 2-aminobenzoxazole (IIIb);
R10 is selected from lower alkyl, halogen, cyano, and lower alkoxy; and
m is 0, 1, or 2.

### Claim 9 (depends on 8)

A compound according to claim 8wherein:
Ar is phenyl or pyrimidinyl, either optionally substituted with one, two, or three groups selected from the group consisting of halo, alkyl, heteroalkyl, alkoxy, nitro, trifluoromethyl, alkylsulfonyl, and optionally-substituted phenyl;
Q is CH2;
R2 and R3 are hydrogen;
R4 is methyl, ethyl, 1-methylethyl, isopropyl, 1-hydroxyethyl or 2-hydroxyethyl; and
R9 is selected from the group consisting of C1-4alkyl, oxo (═O), halogen, and hydroxy.

### Claim 10 (depends on 1)

A compound according to claim 1 wherein:
Uc is IIIc;
R10 is selected from the group consisting of C1-4 alkyl, halogen, cyano, and C1-4 alkoxy; and,
m is 0, 1, or 2.

### Claim 11 (depends on 10)

A compound according to claim 10 wherein:
R2 and R3 are hydrogen; and
R4 is methyl, ethyl, 1-methylethyl, isopropyl, 1-hydroxyethyl or 2-hydroxyethyl.

### Claim 12 (depends on 1)

A compound according to claim 1 wherein:
Uc is IIId;
R10 is selected from the group consisting of C1-4 alkyl, halogen, cyano, and C1-4 alkoxy; and,
m is 0, 1, or 2.

### Claim 13 (depends on 1)

A compound according to claim 1 wherein:
Uc is IIIe;
R10 is selected from the group consisting of C1-4 alkyl, halogen, cyano, and C1-4 alkoxy; and,
m is 0, 1, or 2.

### Claim 14 (depends on 1)

A compound according to claim 1 wherein:
Uc is IIIf;
R10 is selected from the group consisting of C1-4 alkyl, halogen, cyano, and C1-4 alkoxy; and,
m is 0, 1, or 2.

### Claim 15 (depends on 1)

A compound according to claim 1 having the Formula Ia:
wherein,
X is N or N+R9a Z−; Y is CR9a or N;
Z is a pharmaceutically acceptable anion;
R2 and R3 are hydrogen;
R9a is lower alkyl and optionally present;
R21, R22, and R23 are attached to any available carbon atom of the phenyl ring and are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, cyano, trifluoromethyl, trifluoromethoxy, C1-4alkylsulfonyl, amino, and alkylamino; and
n is 1.

### Claim 16 (depends on 15)

A compound according to claim 15 wherein Q is CH2.

### Claim 17 (depends on 15)

A compound according to claim 15 wherein:
R21, R22, and R23, and the phenyl ring to which they are attached, form 4-chlorophenyl or 3,4-dichlorophenyl;
R4 is methyl, ethyl, 1-methylethyl, isopropyl, 1-hydroxyethyl or 2-hydroxyethyl; and
p is 0 or 1.

### Claim 18 (depends on 16)

A compound according to claim 16 in which Uc is selected from one of,
wherein:
R10 is selected from the group consisting of C1-4 alkyl, halogen, cyano, and C1-4 alkoxy; and
m is 0, 1, or 2.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 in admixture with at least one pharmaceutically-acceptable diluent, excipient or carrier.

### Claim 20 (depends on 1)

A method of treatment of a disease selected from the group consisting of Crohn's disease, ulcerative colitis, asthma, hypersensitivity pneumonitis, eosinophilic pneumonias, rhinitis, psoriasis, dermatitis and eczema in a mammal comprising administering a therapeutically effective amount of a CCR-3 antagonist according to claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disease is asthma.
